Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-α-based therapy

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 729-736

  Martinelli, G ^a,c   Testoni, N ^a   Amabile, M ^a   Bonifazi, F ^a   De Vivo, A ^a   Farabegoli, P ^a   Terragna, C ^a   Montefusco, V ^a   Ottaviani, E ^a   Saglio, G ^b   Russo, D ^d   Baccarani, M ^d   Rosti, G ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d NONE

Author keywords

ABMT; BCR ABL; CML; Cytogenetic remission; IFN

Indexed keywords

CYTARABINE; PYRIMIDINE ANTAGONIST; RECOMBINANT ALPHA2A INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; HUMAN; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL;

EID: 0034126172     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702207     Document Type: Article

References (33)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 24: 290-293.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1499.
3. Grosveld G, Verwoerd T, van Agthoven T et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol 1986; 6: 607-616.
4. Shtivelman E, Gale RP, Dreazen O et al. Bcr-abl RNA in patients with chronic myelogenous leukemia. Blood 1987; 69: 971-973.
5. Cross NCP, Lin F, Chase A et al. Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
6. Chissoe SL, Bodenteich A, Wang YF et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995; 27: 67-82.
7. Lee MS, Kantarjian H, Talpaz M et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79: 1920-1923.
8. Martinelli G, Testoni N, Montefusco V et al. Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis. Haematologica 1998; 83: 593-601.
9. Testoni N, Martinelli G, Farabegoli P et al. A new method of 'in cell RT-PCR' for the detection of bcr-abl transcript in chronic myeloid leukemia patients. Blood 1996; 87: 3822-3827.
10. Lin F, Chase A, Bungey J et al. Correlation between the proportion of Philadelphia chromosome positive metaphases and levels of bcr-abl mRNA in chronic myeloid leukaemia. Genes Chromos Cancer 1995; 13: 110-114.
11. Van Rhee F, Marks DI, Lin F et al. Quantification of residual disease in Philadelphia positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
12. Hochhaus A, Lin F, Reiter A et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126-131.
13. Malinge MC, Mahon FX, Delfau MH et al. Quantitative determination of the hybrid bcr-abl RNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol 1992; 82: 701-707.
14. Miggiano MC, Gherlinzoni F, Rosti G et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia 1996; 10: 402-409.
15. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
16. Mahon FX, Daheron L, Malinge MC et al. Polymerase chain reaction detection of residual disease in chronic myeloid leukemia patients in complete cytogenetic remission under interferon with or without chemotherapy. Leukemia 1992; 6: 1232-1234.
17. Martiat P, Maisin D, Philippe M et al. Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Br J Haematol 1990; 75: 355-358.
18. Opalka B, Kloke O, Bartram CR et al. Elimination by interferon-alpha of malignant clone in chronic myeloid leukaemia. Lancet 1989; i: 1334 (letter).
19. Opalka B, Wandl UB, Becher R et al. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon α-2b alone or in combination with interferon γ. Blood 1991; 78: 2188-2193.
20. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975-2984.
21. Pardini S, Addis M, Dore F et al. Interferon-α2a therapy in CML: disappearance of BCR/ABL transcript in a case of long-lasting continuous cytogenetic conversion. Haematologica 1994; 79: 540-541 (review).
22. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114: 532-538.
23. Liberati AM, Donti E, Rosso C et al. Repeated PCR in CML during IFN-α therapy. Eur J Haematol 1994; 52: 152-155.
24. Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 1999; 93: 2755-2759.
25. Goldman JM, Kaeda JS, Cross NCP et al. Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease. Blood 1999; 94: 1484-1486 (letter).
26. Pache G, Schmidt M, Vraetz, T et al. An internally standardized competitive PCR Elisa for the precise quantification of clinical ex vivo gene transfer into hematopoietic stem cells. Blood 1998; 12 (Suppl. 1): 150a (Abstr. 605).
27. Wittor H, Emig M, Betzl G et al. Detection and quantification of bcr-abl transcripts using a novel one-step real-time RT-PCR approach with specific fluorescent hybridization probes. Blood 1998; 12 (Suppl. 1): 73a (Abstr. 298).
28. Kafert S, Ganser A, Eder M. Differential quantification of alternatively spliced mRNAs using isoform specific taqman-probes and real-time RT-PCR. Blood 1998; 12 (Suppl. 1): PAG (Abstr. 3730).
29. Ladetto M, Donovan JW, Schlossman R et al. Limitations of quantitative detection of immunoglobulin heavy chain (IgH) gene rearrangements in multiple myeloma (MM) patients using real-time PCR. Blood 1998; 12 (Suppl. 1): 258a (Abstr. 1056).
30. Seeger K, Kreuzer KA, Schmidt CA et al. Novel 5′ exonuclease-based real-time PCR assay for the detection of TEL-AML1 fusion in childhood acute lymphoblastic leukemia (ALL). Blood 1998; 12 (Suppl. 1): 392a (Abstr. 1622).
31. Bories D, Dumont V, Belhadj K et al. Real-time quantitative RT-PCR monitoring of chronic myelogenous leukemia. Blood 1998; 12 (Suppl. 1): 73a (Abstr. 296).
32. Shah MH, Yu H, Stover EH et al. Simultaneous quantification of cytokine gene expression in multiple organs during endotoxic shock. Blood 1998; 12 (Suppl. 1): 545a (Abstr. 2238).
33. Mensink E, Van de Locht A, Schattenberg E et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.